Pfizer gets bumper $5.3bn order from US for oral COVID drugAlready making big profits from its COVID-19 vaccine, Pfizer looks set to bolt on another big revenue stream Share XPfizer gets bumper $5.3bn order from US for oral COVID drughttps://pharmaphorum.com/news/pfizer-gets-bumper-5-3bn-order-from-us-for-oral-covid-drug/
US signs $1bn order for GSK, Vir’s COVID-19 antibodyThe US has made a sizeable order for GlaxoSmithKline and Vir Biotechnology’s antibody-based COVID-19 treatment sotrovimab said to Share XUS signs $1bn order for GSK, Vir’s COVID-19 antibodyhttps://pharmaphorum.com/news/us-signs-1bn-order-for-gsk-virs-covid-19-antibody/
AbbVie’s Humira tops ICER’s list of unwarranted price hikes againWith drug pricing controls back on the legislative table in the US, the influential Institute for Clinical and Share XAbbVie’s Humira tops ICER’s list of unwarranted price hikes againhttps://pharmaphorum.com/news/abbvies-humira-tops-icers-list-of-unwarranted-price-hikes-again/
J&J finally decides to dismantle its diversified business modelAfter decades of a diversified healthcare business model, Johnson & Johnson has announced it plans to split off Share XJ&J finally decides to dismantle its diversified business modelhttps://pharmaphorum.com/news/jj-finally-decides-to-dismantle-its-diversified-business-model/
AstraZeneca will make ‘modest’ profit from COVID vaccineAstraZeneca has said it plans to start making a small profit from sales of its COVID-19 vaccine Vaxzevria, Share XAstraZeneca will make ‘modest’ profit from COVID vaccinehttps://pharmaphorum.com/news/astrazeneca-will-make-modest-profit-from-covid-vaccine/
Valneva gets EU deal for COVID jab, and may sue UKShares in France’s Valneva leaped after it got an EU order to supply 60 million doses of its Share XValneva gets EU deal for COVID jab, and may sue UKhttps://pharmaphorum.com/news/valneva-gets-eu-deal-for-covid-jab-and-may-sue-uk/
Pfizer strikes $1.2bn licensing deal for Biohaven migraine drugPfizer has bolstered its central nervous system (CNS) drugs portfolio with a $1.2 billion deal to claim rights Share XPfizer strikes $1.2bn licensing deal for Biohaven migraine drughttps://pharmaphorum.com/news/pfizer-strikes-1-2bn-licensing-deal-for-biohaven-migraine-drug/
US buys another $1 billion-worth of Merck’s COVID capsuleThe US federal government has ordered another 1.4 million doses of Merck & Co and Ridgeback Biotherapeutics’ oral Share XUS buys another $1 billion-worth of Merck’s COVID capsulehttps://pharmaphorum.com/news/us-buys-another-1-billion-worth-of-mercks-covid-capsule/
Swiss socialists say government should buy SandozSwitzerland’s Social Democratic Party has argued that the government should step in and acquire Novartis’ generics unit Sandoz Share XSwiss socialists say government should buy Sandozhttps://pharmaphorum.com/news/swiss-socialists-say-government-should-buy-sandoz/
Democrats agree last-ditch deal to save drug pricing plansUnder fire for abandoning a plan to allow Medicare to negotiate drug pricing, Democrats in the Senate have Share XDemocrats agree last-ditch deal to save drug pricing planshttps://pharmaphorum.com/news/democrats-agree-last-ditch-deal-to-save-drug-pricing-plans/
Novartis finally sells Roche stake, for almost $21 billionAfter more than 20 years, Novartis has finally decided to sell its substantial share in fellow Swiss pharma Share XNovartis finally sells Roche stake, for almost $21 billionhttps://pharmaphorum.com/news/novartis-finally-sells-roche-stake-for-almost-21-billion/
Pfizer’s COVID jab sales swell again, with $36bn forecast for 2021Rocketing sales of COVID-19 vaccine Comirnaty have allowed Pfizer to raise its full-year forecasts for the shot once Share XPfizer’s COVID jab sales swell again, with $36bn forecast for 2021https://pharmaphorum.com/news/pfizers-covid-jab-sales-swell-again-with-36bn-forecast-for-2021/
White House backtracks on medicine price control plansPresident Joe Biden has jettisoned a raft of policy proposals aimed at curbing the price of prescription medicines Share XWhite House backtracks on medicine price control planshttps://pharmaphorum.com/news/white-house-backtracks-on-medicine-price-control-plans/
Novartis looking into future of its Sandoz’ generics businessNovartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – Share XNovartis looking into future of its Sandoz’ generics businesshttps://pharmaphorum.com/news/novartis-looking-into-future-of-its-sandoz-generics-business/
Acceleron investors dig their heels in on Merck takeover bidActivist investors are pushing back against Merck & Co’s recent $11.5 billion deal to acquire Acceleron Pharma, arguing Share XAcceleron investors dig their heels in on Merck takeover bidhttps://pharmaphorum.com/news/acceleron-investors-dig-their-heels-in-on-merck-takeover-bid/
Biogen’s Aduhelm rollout goes from bad to worseAnalysts were predicting sales of Biogen’s recently approved Alzheimer’s therapy Aduhelm may start to gather a little momentum Share XBiogen’s Aduhelm rollout goes from bad to worsehttps://pharmaphorum.com/news/biogens-aduhelm-rollout-goes-from-bad-to-worse/
Delta variant keeps Roche diagnostics sales sky highHigh demand for COVID-19 diagnostics driven by the delta variant has led to rocketing sales at Roche’s diagnostics Share XDelta variant keeps Roche diagnostics sales sky highhttps://pharmaphorum.com/news/delta-variant-keeps-roche-diagnostics-sales-sky-high/
J&J mulls switch from non-profit status for COVID jabJohnson & Johnson has been offering its COVID-19 vaccine for sale on a no-profit basis since it became Share XJ&J mulls switch from non-profit status for COVID jabhttps://pharmaphorum.com/news/jj-mulls-switch-from-non-profit-status-for-covid-jab/
